Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115144) titled 'Prospective phase II study on the efficacy and safety of iparomlimab and tuvonralimab combined with docetaxel in patients with advanced or metastatic SMARCA4-deficient NSCLC' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Dongguan People's Hospital
Condition:
recurrent or metastatic SMARCA4-deficient non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-01-01
Target Sample Size: Experimental group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=301994
P...